Painchek Ltd (ASX: PCK) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Painchek Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $55.39 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 209.01 million
Earnings per share -0.044
Dividend per share N/A
Year To Date Return -5.17%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Painchek Ltd (ASX: PCK)
    Latest News

    A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares
    Healthcare Shares

    Junior health-tech firm's shares race to 12-month high on US regulatory clearance

    This healthcare company can start selling in the US after a key regulatory hurdle was overcome.

    Read more »

    Scientist looking at a laptop thinking about the share price performance.
    Healthcare Shares

    Why did this ASX biotech stock explode 36% today?

    This ASX nano-cap healthcare share has leapt 47% in just a week.

    Read more »

    Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
    Share Gainers

    What the heck is going on with the PainChek (ASX:PCK) share price?

    It's been a strange few days on the ASX for PainChek...

    Read more »

    A boy looks up and points his fingers to the sky in celebration pose.
    Healthcare Shares

    The PainChek (ASX:PCK) share price is rising on its latest announcement

    Shares in PainChek Ltd are gaining today after the company has received regulatory clearances for its app, PainChek Infant.

    Read more »

    A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
    Healthcare Shares

    Why the Painchek (ASX:PCK) share price is charging 13% higher

    The PainChek Ltd (ASX: PCK) share price is soaring today after the app developer received TGA approval for its latest…

    Read more »

    high share price
    Share Gainers

    Why Lake Resources, PainChek, Z Energy, & Zip shares are rising today

    Lake Resources N.L (ASX:LKE) and Zip Co Ltd (ASX:Z1P) are two of four ASX shares climbing higher on Wednesday. Here's…

    Read more »

    Starpharma share price A doctor or medical expert in COVID-19 protection flexes his muscle, indicating growth or strong share price movement in ASX medical, biotech and health companies
    Share Market News

    Why the Painchek (ASX:PCK) share price is edging higher today

    The PainChek (ASX: PCK) share price rose today against the market as the company announced its half-year report. We take…

    Read more »

    medical asx share price represented by doctor giving thumbs up
    Share Market News

    Why the Painchek (ASX:PCK) share price lifted today

    The Painchek (ASX: PCK) share price was up more than 4% at close of trade after the company released its…

    Read more »

    Share Fallers

    PainChek (ASX:PCK) share price lower despite Ramsay (ASX:RHC) partnership

    The PainChek Ltd (ASX:PCK) share price is dropping lower on Friday despite announcing a partnership with Ramsay Health Care Limited…

    Read more »

    PCK ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Painchek Ltd

    Painchek Ltd is engaged in the development and commercialization of mobile medical device applications that provide pain assessment for individuals who are unable to communicate pain with carers. It operates in one segment, namely the saleof its pain assessment solutions. Its geographic segments include Australia, the United Kingdom, and Other countries, of which it generates the majority of its revenue from Australia.

    PCK Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    14 Jan 2026 $0.27 $0.01 3.85% 88,899 $0.27 $0.27 $0.26
    13 Jan 2026 $0.26 $-0.02 -7.27% 324,775 $0.28 $0.28 $0.26
    12 Jan 2026 $0.28 $-0.01 -3.54% 124,597 $0.28 $0.28 $0.27
    09 Jan 2026 $0.28 $0.00 0.00% 76,957 $0.28 $0.29 $0.28
    08 Jan 2026 $0.29 $0.01 3.70% 117,632 $0.28 $0.29 $0.28
    07 Jan 2026 $0.27 $-0.01 -3.64% 168,877 $0.28 $0.28 $0.27
    06 Jan 2026 $0.28 $-0.02 -6.78% 85,737 $0.29 $0.30 $0.28
    05 Jan 2026 $0.30 $0.01 3.51% 91,265 $0.29 $0.30 $0.29
    02 Jan 2026 $0.29 $-0.01 -3.45% 214,487 $0.29 $0.30 $0.28
    31 Dec 2025 $0.29 $-0.02 -6.45% 56,149 $0.30 $0.30 $0.29
    30 Dec 2025 $0.31 $0.02 6.90% 94,627 $0.29 $0.31 $0.29
    29 Dec 2025 $0.29 $-0.01 -3.39% 196,078 $0.31 $0.31 $0.28
    24 Dec 2025 $0.30 $0.00 0.00% 16,782 $0.30 $0.30 $0.30
    23 Dec 2025 $0.30 $-0.01 -3.33% 102,960 $0.30 $0.30 $0.29
    22 Dec 2025 $0.30 $0.02 7.14% 137,570 $0.30 $0.31 $0.29
    19 Dec 2025 $0.28 $0.00 0.00% 57,359 $0.28 $0.30 $0.28
    18 Dec 2025 $0.28 $-0.03 -9.68% 108,011 $0.30 $0.30 $0.28
    17 Dec 2025 $0.31 $0.03 10.91% 69,631 $0.28 $0.31 $0.28
    16 Dec 2025 $0.28 $-0.04 -12.70% 313,962 $0.31 $0.32 $0.28

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    22 Dec 2025 Philip Daffas Issued 147,059 $50,000
    Placement.
    22 Dec 2025 Cynthia Payne Issued 29,412 $10,000
    Placement.
    19 Dec 2025 Cynthia Payne Expiry 18,691 $5,233
    Options expired.
    19 Dec 2025 Ross Harricks Expiry 104,014 $29,123
    Options expired.
    19 Dec 2025 Philip Daffas Expiry 200,000 $56,000
    Options expired.
    19 Dec 2025 John Murray Expiry 40,000 $11,200
    Options expired.
    19 Dec 2025 Adam Davey Expiry 76,728 $21,483
    Options expired.
    22 Oct 2025 Philip Daffas Expiry 4,804,177 $245,013
    As advised by the company. Lapsed, 9071017 Rights
    22 Oct 2025 Philip Daffas Exercise 2,360,718 $120,396
    Conversion of securities. 6,710,299 Performance Rights
    22 Oct 2025 Philip Daffas Issued 2,360,718 $120,396
    Conversion of securities.
    26 Sep 2025 John Murray Buy 1,133,144 $61,189
    Conversion of securities. As per announcement on 01-10-2025
    26 Sep 2025 John Murray Exercise 1,133,144 $61,189
    Conversion of securities.
    12 Sep 2025 Adam Davey Transfer 1,930,602 $97,495
    Off-market transfer. Assuming off market transfer of shares
    12 Sep 2025 Adam Davey Buy 566,572 $28,611
    Conversion of securities.
    12 Sep 2025 Adam Davey Transfer 1,930,602 $97,495
    Off-market transfer. Assuming off market transfer of shares, as per announcement on 19-09-2025
    12 Sep 2025 Adam Davey Exercise 566,572 $28,611
    Conversion of securities.
    12 Sep 2025 Ross Harricks Exercise 566,572 $28,611
    Conversion of securities.
    12 Sep 2025 Ross Harricks Buy 566,572 $28,611
    Conversion of securities.
    12 Sep 2025 Cynthia Payne Exercise 566,572 $28,611
    Conversion of securities.
    12 Sep 2025 Cynthia Payne Buy 566,572 $28,611
    Conversion of securities.
    30 Jun 2025 Cynthia Payne Issued 566,572 $25,495
    Issue of securities. 566,572 Performance Rights
    30 Jun 2025 Philip Daffas Issued 7,082,154 $318,696
    Issue of securities. 13,875,194 Performance Rights
    30 Jun 2025 Ross Harricks Issued 566,572 $25,495
    Issue of securities. 566,572 Performance Rights
    30 Jun 2025 Adam Davey Issued 566,572 $25,495
    Issue of securities. 566,572 Performance Rights
    30 Jun 2025 John Murray Issued 1,133,144 $50,991
    Issue of securities. 1,133,144 Performance Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Adam Stuart Davey Non-Executive Director Sep 2014
    Mr Davey's expertise spans over 25 years and includes capital raising (both private and public), mergers and acquisition, asset sales and purchases, transaction due diligence and director duties. Mr Davey is a Director of Wealth Management at Canaccord Genuity Patersons Limited. Mr Davey has been involved in growing businesses in both the industrial and mining sector. Mr Davey is a non-executive director of the Agency Group Australia Ltd and was a director of Ensurance Limited until 2nd July 2021.
    Mr Philip Daffas Chief Executive OfficerManaging Director Sep 2016
    Mr Daffas has an international career spanning more than 25 years with blue-chip healthcare corporates and novel technology start-up companies. Philip has held senior global business leader positions in Europe, US and Australia. He has been involved in building businesses, growing market share and developing customer and industry relationships in each sector on a global basis. Philip's earlier experience was in Europe with IVAC infusion systems and Shiley cardiopulmonary He subsequently joined Boehringer Mannheim, initially in the UK managing their diagnostics business and subsequently was promoted to a Global Marketing role in the Diabetes Care business cased in Mannheim, Germany. In 1997 Philip joined Cochlear in the UK as the European Sales and Marketing Manager and subsequently was promoted in 2000 to the VP Global Marketing role based in Sydney, Australia Other roles in Australia have included General Manager with Roche Diagnostics, Managing Director at Bio Rad Laboratories and CEO of Applied Physiology, an Australian software start-up company in the intensive care monitoring sector.
    Mr John Murray Non-Executive ChairmanNon-Executive Director Sep 2016
    Mr Murray has 25 years of experience in private equity and venture capital and was a co-founder and Managing Partner of Technology Venture Partners; one of the original venture capital firms in Australia. Mr Murray is a past chairman of the Australian Venture Capital Association. Mr Murray has experience as an investor and a non-executive director of high growth, technology-based companies. He possesses an understanding of global trends in technology and its impact on a variety of industries. He is a past Chairman of a private, residential aged care business in Australia. Mr Murray also has 12 years of experience in executive roles in corporate banking, accounting and IT services industries. Mr Murray has been on the Board of several technology rollouts and exits including online travel play Viator, which was acquired by TripAdvisor for approximately US$200 million in 2014. Mr Murray is a director of UK AIM listed company Seeing Machines Ltd.
    Mr Ross Harricks Non-Executive Director Sep 2016
    Mr Harricks' experience in the commercialization of medical products spans over forty years and over three continents. His experience includes the marketing and commercializing of the computed technology scanner (CT or CAT scanner) in Australia, where he headed up the EMI Electronics Group as General Manager. His remit included developing EMI's medical business in this region. n 1983, Mr Harricks joined the Nucleus Group as Group Marketing Executive, and later became President the two Nucleus Group subsidiaries in United States marketing medical equipment and products. scientific and engineering computing products. In 1989 in the US, Mr Harricks was the CEO of a venture capital-backed start-up company developing specialist scientific and medical lasers.
    Ms Cynthia Payne Non-Executive Director Mar 2022
    Ms Payne brings 30 years executive leadership experience as well as board and operational experience in residential and home aged care services in Australia. That experience includes over 16 years as CEO for a private aged care Provider in NSW and before that head of operation manager for a large Not for Profit with home care, residential and retirement living portfolios. She is the founder and Managing Director of Anchor Excellence, a consultancy firm in the aged care services industry in Australia that advises boards and management on operational and compliance best practices. Cynthia is a board advisor to Total Constructions Pty Ltd, a former Director of the Heart Foundation and past Chair of Business Excellence Australia
    Ms Natalie Sylvia Climo Company Secretary Jan 2024
    -
    Natalie Sylvia Climo Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Peters Investments Pty Ltd 133,481,250 6.47%
    HSBC Custody Nominees (Australia) Limited 51,571,240 2.50%
    Double Red Investments Pty Ltd <Double Red Investments A/C> 49,500,000 2.40%
    BNP Paribas Noms Pty Ltd 43,243,141 2.10%
    Harlex Farms Pty Ltd <The T H Martin Family A/C> 42,321,361 2.05%
    BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 38,850,030 1.88%
    J&E Consulting Pty Ltd 38,082,712 1.85%
    Dr Kreshnik Hoti 37,717,411 1.83%
    Mr Mustafa Abdul Wahed Atee 37,003,125 1.79%
    Citicorp Nominees Pty Limited 31,833,154 1.54%
    Cache (Wa) Pty Ltd 31,394,405 1.52%
    Gleneden Nominees Pty Ltd 27,407,407 1.33%
    Mr Philip Daffas 27,310,946 1.32%
    Mr Craig Robert Williamson 25,542,606 1.24%
    G & G Chilcott Pty Ltd <G & G Chilcott S/F A/C> 24,176,518 1.17%
    Ms Eloise Kathleen Jennings & Mr Andrew John Hopkins <Jennings Hopkins Discret A/C> 23,724,174 1.15%
    Grazian Pty Ltd <The Ian Murie Super Fund A/C> 22,500,000 1.09%
    Paranji Super Fund Pty Ltd <Paranji Superfund A/C> 19,575,256 0.95%
    Mr Rodney James Wellstead 19,474,679 0.94%
    Mr Eddy Roelof Paul De Vries & Mrs Penelope Gail De Vries <Erp&Pg De Vries Family A/C> 17,790,533 0.85%

    Profile

    since

    Note